|
on Intellectual Property Rights |
| By: | Grassano Nicola; M'barek Robert (European Commission - JRC) |
| Abstract: | Pharmaceuticals and Medical Technologies (PMTs) patents represent 12.6% of the total IP5 patent families filed worldwide in the period 2010-2020. The US are the biggest player in the field, filing 25.1% of all PMTs IP5 patent families 2010-2020. The EU is second with 17.2%, followed by Japan (8.5%), South Korea (4.4%) and China (3.2%). Among EU Member States, Germany has by far the highest number of PMTs IP5 patent families filed in the observed period, accounting for 36% of all the patents filed by the EU 2010-2020. |
| Date: | 2025–06 |
| URL: | https://d.repec.org/n?u=RePEc:ipt:iptwpa:jrc142609 |
| By: | Pelissier Pierre-Mathieu (European Commission - JRC); Grabowska Marcelina (European Commission - JRC); Bergamini Michela (European Commission - JRC) |
| Abstract: | This report presents a patent landscape analysis investigating the innovation trends within the industrial biotechnology (IB) sector from 2015 to 2020. The study's primary objective is to identify the geographical hotspots of innovation, the key players, and the role of different types of organizations in driving technological advancements in IB. By employing a methodology that includes data retrieval through the Technology Innovation Monitoring (TIM) tool and careful selection of keywords and Cooperative Patent Classification (CPC) terms, the report categorizes patents across five technological areas pertinent to IB. The geographical scope of the analysis encompasses major global players as well as the European Union, providing a broad view of the innovation landscape. The report also introduces an online dashboard to facilitate further analysis and exploration of the data. This study serves as a resource for policymakers, industry stakeholders, and researchers, offering insights that can inform strategic planning and decision-making in the evolving field of industrial biotechnology. |
| Date: | 2025–06 |
| URL: | https://d.repec.org/n?u=RePEc:ipt:iptwpa:jrc139154 |
| By: | Devarakonda, S.V. (Tilburg University, School of Economics and Management); Goossen, Martin (Tilburg University, School of Economics and Management); Mulotte, Louis (Tilburg University, School of Economics and Management) |
| Date: | 2024 |
| URL: | https://d.repec.org/n?u=RePEc:tiu:tiutis:4e9af8a0-0e1c-4780-a24e-6d1814f7d0cb |
| By: | Jan Malek; Jo Seldeslachts; Reinhilde Veugelers |
| Abstract: | This paper provides empirical evidence on which M&A deals spur innovation, and which stifle it. To do so, we consider not only the product market position of the acquiring firm, but also the position of both target and acquirer in the technology space. Focusing on the antidiabetic drugs market, our dataset tracks the lifecycle and patenting of all individual antidiabetic projects in development between 1997 and 2017. We show that most terminations of acquired projects occur while the projects are still far from product market entry. Nevertheless, a number of these early-stage acquisitions have a positive impact on innovation. These cases arise when incumbents acquire projects close to their own projects in product markets, but only if these projects are also close in technology markets. Those deals are associated with increased subsequent patenting, which is consistent with the exploitation of technological synergies. Our results point to the crucial role of combining both product market and technology market positions in assessing the innovation effects of pharmaceutical M&As. |
| Keywords: | M&As, innovation, R&D, pharmaceutics, technology, novelty, patents |
| JEL: | L41 L65 O31 |
| Date: | 2025 |
| URL: | https://d.repec.org/n?u=RePEc:diw:diwwpp:dp2128 |